Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSILOTRAZ: Psilocybin and Trazodone in Treatment-resistant Depression
NCT07210112Phase 2Recruiting
- Sponsor
- Centre Hospitalier Sainte-Anne
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in treatment-resistant depression (TRD) (4 arms), sponsored by Centre Hospitalier Sainte-Anne. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 1 month. Started Jun 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07210112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07210112.